February 17th 2024
A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
KTE-C19 Treatment Shows Impressive Responses in Aggressive Lymphomas
December 6th 2016Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma, according to findings from the multicenter phase II ZUMA-1 study.
Read More
Pembrolizumab Triplet Induces Durable Responses for Multiple Myeloma
December 5th 2016Pembrolizumab (Keytruda), pomalidomide (Pomalyst), and dexamethasone had an objective response rate of 65% and a very good partial response or better rate of 29% for patients with relapsed/refractory multiple myeloma, according to phase II findings presented at the 2016 ASH Annual Meeting.
Read More
Nivolumab/Ibrutinib Combo Shows Encouraging Activity for Richter Transformation
December 4th 2016Treatment with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica) showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.
Read More
The Evolving Role of Mouse Models in Immunotherapy
December 2nd 2016While mouse models have historically been helpful in the research of immunotherapies, genetic testing and clinical models may play a role in the near future. These pre-clinical models have been criticized for some of their limitations, but Marcus Bosenberg, MD, PhD, confirms their current relevance and clinical applicability.<br />
Read More
Nivolumab Combinations Feasible for Newly Diagnosed GBM
November 20th 2016The PD-1 inhibitor nivolumab was successfully combined with radiotherapy alone or concurrently with temozolomide for patients with newly-diagnosed glioblastoma multiforme in cohorts 1c and 1d from the phase I CheckMate-143 study.
Read More
PD-1/CTLA-4 Inhibitor Combination Highly Effective for Metastatic Bladder Cancer
November 15th 2016Treatment with the combination of nivolumab and ipilimumab at selected doses led to a high response rate and marked improvements in overall survival for patients with pretreated metastatic urothelial carcinoma.
Read More
Sonja Althammer Discusses Biomarkers for Durvalumab in Lung Cancer
November 13th 2016Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non–small cell lung cancer who respond best to treatment with the PD-L1 inhibitor durvalumab.
Watch
Radiomics Could Play Important Predictive Role in Patient Outcomes in Sarcoma
November 12th 2016Though surgical resection and radiation therapy remain at the forefront of the treatment for localized disease, accurately predicting outcomes for individual patients remains a challenge, which radiomics, an emerging research field, hopes to alleviate.
Read More
The CheckPoints Let Immunotherapy Experts Cut Loose
November 12th 2016The CheckPoints, which are considered the official house band of the Society for Immunotherapy of Cancer (SITC), performs every year at the annual meeting, as well as at a SITC sponsored event at the ASCO annual meeting each year.
Read More
Novel Immune Checkpoint Identified as Promising Target for Blockade Strategies
November 12th 2016A new immune checkpoint called PVRIG has emerged as a ripe target for anticancer therapy in solid tumors and an antibody that blocks its ability to suppress an antitumor response is in development.<br />
Read More
Pembrolizumab Plus Cyclophosphamide Shows Limited Benefit in Diverse Types of Sarcoma
November 12th 2016Pembrolizumab plus low dose metronomic cyclophosphamide demonstrated limited patient benefit in adult patients with diverse types of unresectable locally advanced or metastatic sarcoma.<br />
Read More
Nivolumab/Pazopanib Combo Shows Promise in Relapsed Sarcoma
November 12th 2016Clinical benefit, including partial response and stable disease, was observed in 11 of 20 patients with relapsed metastatic sarcoma following nivolumab treatment that was administered either alone or in combination with pazopanib.
Read More
Current and Emerging Immunotherapeutic Strategies in Melanoma
November 12th 2016Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, discusses current and emerging immunotherapeutic strategies in the field of melanoma during an interview at the 34th Annual Chemotherapy Foundation Symposium<sup>TM</sup>.
Watch
Expert Discusses Pembrolizumab Potential in Sarcoma
November 12th 2016Updated results of the multicenter phase II study SARC028 demonstrate both a favorable safety profile as well as encouraging efficacy for the use pembrolizumab (Keytruda) as a treatment for patients with advanced sarcomas.
Read More
Nivolumab Improves Survival in Advanced Gastric Cancer
November 11th 2016The PD-1 inhibitor nivolumab extended overall survival versus placebo for patients who were refractory or intolerant to standard therapy with unresectable, advanced, or recurrent gastric cancer, according to topline data from the phase III ONO-4538-12 trial.
Read More
Pembrolizumab Demonstrates Anti-Tumor Activity in Sarcoma Subtypes
November 11th 2016Treatment with pembrolizumab, an immunotherapeutic agent approved in melanoma, lung, and head and neck cancer, and which is undergoing investigation in several other cancer types, reduced the size of tumors in patients with a specific soft tissue sarcoma.
Read More